Non-IRA Functional Evaluation With AccuFFRangio in NSTE-ACS

Diagnostic Performance and Prognostic Ability of AccuFFRangio for Non-IRA in NSTE-ACS Patients

This is a prospective, single-center clinical trial. AccuFFRangio (ArteryFlow Technology Co., Ltd., Hangzhou, China) is a novel method for evaluating the functional significance of coronary stenosis by computing the pressure in the vessel based on angiographic images. The purpose of this study is to investigate the diagnostic performance and prognostic ability of AccuFFRangio for non-IRA in NSTE-ACS patients.

Inclusion Criteria:

• 18 Years and older
• Non-ST-segment elevation acute coronary syndrome patients with at least 1 non-IRA
• Diameter stenosis of 50%-90% by visual estimate
• Reference vessel size > 2 mm in stenotic segment by visual estimate

Exclusion Criteria:

• LVEF ≤ 40%
• eGFR < 60 mL/min
• Allergy to contrast media, adenosine
• Prior CABG